Русский
The effect of increased hepcidin expression on the pharmacokinetics of ferrous sulfate in patients with iron deficiency on the background of anemia of chronic diseases
DOI: https://dx.doi.org/10.18565/therapy.2022.4.56-61
Osipyan Е.Ae., Makhova A.A., Drozdov V.N., Shikh E.V.
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)
The aim is to study the pharmacokinetics of iron preparations in patients with ID which arised on the background of anemia of chronic diseases (ACD), comparatively with patients with isolated iron deficiency anemia (IIDA).
Material and methods. A comparison of pharmacokinetics of iron sulfate in 15 female patients with IIDA and 15 female patients with ID are on the background of ACD was made.
Results. The main indicators of iron exchange in the study groups were not significantly different, except for the level of iron-regulating protein hepcidin in patients with ACD + ID comparatively to IIDA patients, 6,1±3,6 versus 15,1±7,3 ng/ml. The area under the curve (AUC) of basal level of iron was 150,96±43,97 μmol×hour/l in patients with IIDA and 112,65±15,88 μmol×hour/l in patients with ACD + ID. After taking 200 mg of iron sulfate AUC increased to 310,18±73,02 μmol×hour/l in patients with IIDA and up to 141,4 μmol×hour/l in patients with ACD + ID. In patients with IIDA, the value of the maximum concentration (Cmax) of iron sulfate in blood (21,2 μmol/l) was achieved more quickly – after 3,1 hours after medicine intake; in patients with ACD and ID Cmax (5,2 μmol/l) was achieved only after 5,6 hours.
Conclusion. The obtained data indicate the effect of increased influence of hepcidin at pharmacokinetics of iron preparations in patients with ACD, accompanied by ID.
Literature
1. Kassebaum N.J., Jasrasaria R., Naghavi M. et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014; 123(5): 615–24. https://dx.doi.org/10.1182/blood-2013-06-508325. 2. Nemeth E., Ganz T. Hepcidin and iron-loading anemias. Haematologica. 2006; 91(6): 727–32. https://dx.doi.org/10.3324/%25x. 3. Nemeth E., Valore E.V., Territo M. et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101(7): 2461–63. https://dx.doi.org/10.1182/blood-2002-10-3235. 4. Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9): 1271–76. https://dx.doi.org/10.1172/JCI20945. 5. Nicolas G., Chauvet C., Viatte L. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110(7): 1037–44. https://dx.doi.org/10.1172/JCI15686. 6. Weinstein D.A, Roy C.N., Fleming M.D. et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002; 100(10): 3776–81. https://dx.doi.org/10.1182/blood-2002- 04-1260. 7. Nicolas G., Viatte L., Lou D.-Q. et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nature Genetics. 2003; 34(1): 97–101. https://dx.doi.org/10.1038/ng1150. 8. Arezes J., Nemeth E. Hepcidin and iron disorders: new biology and clinical approaches. Int J Lab Hematol. 2015; 37(Suppl 1): 92–98. https://dx.doi.org/10.1111/ijlh.12358. 9. Armitage A. E., Eddowes L.A, Gileadi U. et al. Hepcidin regulation by innate immune and infectious stimuli. Blood. 2011; 118(15): 4129–39. https://dx.doi.org/10.1182/blood-2011-04-351957. 10. Левин А.А., Казюкова Т.В., Цветаева Н.В. с соавт. Гепсидин как регулятор гомеостаза железа. Педиатрия. Журнал им. Г.Н. Сперанского. 2008; 1; 11. [Levina A.A., Kazyukova T.V., Tsvetaeva N.V. et al. Hepsidin as regulator of iron homeostasis. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatrics. Journal named after G.N. Speransky. 2008; 1; 11 (In Russ.)]. 11. Fleming R.E., Sly W.S. Ferroportin mutation in autosomal dominant hemochromatosis: Loss of function, gain in understanding. J Clin Invest. 2001; 108(4): 521–22. https://dx.doi.org/10.1172/JCI13739. 12. Moretti D., Goede J.S., Zeder C. et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twicedaily doses in iron-depleted young women. Blood. 2015; 126(17): 1981–89. https://dx.doi.org/10.1182/blood-2015-05-642223 13. Zimmermann M.B., Troesch B., Biebinger R. et al. Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am J Clin Nutr. 2009; 90(5): 1280–87. https://dx.doi.org/10.3945/ajcn.2009.28129. 14. Roe M.A., Collings R., Dainty J.R. et al. Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. Am J Clin Nutr. 2009; 89(4): 1088–91. https://dx.doi.org/10.3945/ajcn.2008.27297.
About the Autors
Elena Ae. Osipyan, postgraduate student of the Department of clinical pharmacology and propaedeutics of internal diseases, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Siechenov University). Address: 119991, Moscow, 8/2 Trubetskaya Str. E-mail: lenaosipyan@gmail.com.
ORCID: https://orcid.org/0000-0003-2134-0197
Anna A. Makhova, Dr. med. habil., associate professor, associate professor of the Department of clinical pharmacology and propaedeutics of internal diseases, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Siechenov University). Address: 119991, Moscow, 8/2 Trubetskaya Str.
ORCID: https://orcid.org/0000-0001-9817-9886
Vladimir N. Drozdov, Dr. med. habil., professor, professor of the Department of clinical pharmacology and propaedeutics of internal diseases, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Siechenov University). Address: 119991, Moscow, 8/2 Trubetskaya Str. ORCID: https://orcid.org/0000-0002-0535-2916
Evgenia V. Shikh, Dr. med. habil., professor, head of the Department of clinical pharmacology and propaedeutics of internal diseases, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University). Address: 119991, Moscow, 8/2 Trubetskaya Str. ORCID: https://orcid.org/0000-0001-6589-7654
Similar Articles
